<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280629</url>
  </required_header>
  <id_info>
    <org_study_id>PCG-4/UCR</org_study_id>
    <secondary_id>2013-001205-84</secondary_id>
    <nct_id>NCT02280629</nct_id>
  </id_info>
  <brief_title>Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)</brief_title>
  <acronym>PROTECT-2</acronym>
  <official_title>Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 48-weeks Treatment With Gastro-resistant Phosphatidylcholine (LT-02) Versus Placebo Versus Mesalamine for Maintenance of Remission in Patients With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prove the superiority of a 48-weeks treatment with 3.2 g/day
      delayed-release phosphatidylcholine (LT-02) versus placebo for the maintenance of remission
      in patients with ulcerative colitis (UC)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who are relapse-free and are not a treatment failure</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the total mDAI</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>LT-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesalamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LT-02 PLACEBO twice daily AND 500mg mesalamine PLACEBO three-times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LT-02</intervention_name>
    <description>LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily</description>
    <arm_group_label>LT-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamine</intervention_name>
    <description>LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily</description>
    <arm_group_label>Mesalamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Signed informed consent

          -  Men or women, 18 to 70 years of age

          -  Historically confirmed diagnosis of UC by endoscopy and histology

          -  Patients being in clinical and endoscopical remission at baseline

          -  Negative pregnancy test in females of childbearing potential at baseline visit

        Major Exclusion Criteria:

          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,
             microscopic colitis (i.e., collagenous colitis and lymphocytic colitis), diverticular
             disease associated colitis

          -  Toxic megacolon or fulminant colitis

          -  Colon resection

          -  Malabsorption syndromes

          -  Celiac disease

          -  Bleeding hemorrhoids

          -  Other inflammatory or bleeding disorders of the colon and intestine, or diseases that
             may cause diarrhea or gastrointestinal bleeding

          -  History or presence of ischemic heart disease, myocardial infarction, peripheral
             arterial disease, ischemic stroke, or transient ischemic attack

          -  Any severe concomitant renal, endocrine, or psychiatric disorder, which in the
             opinion of the investigator might have an influence on the patient's compliance or
             the interpretation of the results

          -  Any relevant known systemic disease (e.g., AIDS, active tuberculosis)

          -  Severe co-morbidity substantially reducing life expectancy

          -  History of cancer in the last five years

          -  Abnormal hepatic function at screening visit, liver cirrhosis

          -  Abnormal renal function at screening visit

          -  Patients with known hypersensitivity to soy

          -  Known intolerance/hypersensitivity to Investigational Medicinal Product (IMP: LT-02
             or mesalamine)

          -  Treatment with steroids (oral, inhalative, or intravenous [IV]), cyclosporine or
             tacrolimus within last 4 weeks prior to randomization

          -  Treatment with methotrexate within last 6 weeks prior to randomization

          -  Treatment with TNF-alpha-antagonists, azathioprine, 6-mercaptopurine, or
             anti-integrin therapy within last 8 weeks prior to randomization

          -  Treatment with rectal mesalamine or corticosteroid formulations within last 2 weeks
             prior to randomization

          -  Treatment with other investigational drug within last 12 weeks prior to randomization
             except LT-02

          -  Existing or intended pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Dignass, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Agaplesion Markus Krankenhaus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidrun Heinemann</last_name>
    <email>heidrun.heinemann@drfalkpharma.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roland Greinwald, PhD</last_name>
    <email>roland.greinwald@drfalkpharma.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Agaplesion Markus-Krankenhaus</name>
      <address>
        <city>Frankfurt a.M.</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Dignass, Prof. Dr.</last_name>
      <email>axel.dignass@fdk.info</email>
    </contact>
    <investigator>
      <last_name>Axel Dignass, Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>October 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
